Pfizer reported strong Phase 3 oncology data for BRAFTOVI, TALZENNA, and LORBRENA, demonstrating improved survival rates across multiple cancers. The company also announced positive mid-stage results for berobenatide, an obesity therapy, with plans for 10 Phase 3 trials to develop the first monthly GLP-1 treatment. Furthermore, Pfizer secured new FDA approvals alongside significant acquisition and collaboration activity involving other industry giants like Johnson & Johnson and Roche.
Pfizer has initiated Phase 3 clinical trials for its PG4 vaccine candidate, aiming to bolster its pediatric portfolio ahead of key patent expirations.
Read the full storyPfizer's experimental drug sigvotatug vedotin failed to meet its primary survival endpoint in a Phase 3 lung cancer trial, impacting its oncology outlook.
Pfizer, Lilly, and Takeda secure key regulatory wins as industry giants J&J and Roche drive a new wave of strategic consolidation and dealmaking.
Pfizer revealed positive mid-stage results for its GLP-1 candidate berobenatide, planning 10 Phase 3 trials to pioneer a monthly dosing schedule for weight loss.
Pfizer reported successful Phase 3 trial results for its oncology pipeline, supporting a strategic pivot to offset declining COVID-19 product revenues.